ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

FDA News: Agency Abandons Plan To Merge Two Offices, Citing Delay Request From Employees’ Union

June 19, 1998

Univ. Of Pittsburgh Plans Molecular Medicine Institute.

January 25, 2002

FDA Approves Generic Oncology Injectable Currently In Shortage

September 27, 2013

In Brief: Resolution wasn’t Strong Enough, Reizen Though; Two More chemicals reported Out of Bioassay

June 3, 1977

Science Fellowships Available; Grants For Former Soviet Scientists

August 16, 1996

NCI Programs: Institute Funds 24 DNA Microarray Centers

September 24, 1999